BRIEF-Immunomedics announces publication of cancer drug data
August 21, 2017 at 08:19 AM EDT
* Immunomedics announces publication of phase 2 results with labetuzumab govitecan (immu-130) that demonstrate promising efficacy as a single agent in patients with metastatic colorectal cancer
